Unknown

Dataset Information

0

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

ABSTRACT: We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300?mg first week, followed by 1000?mg every 8 weeks for up to 2 years) or observation. Median follow-up duration was 40.9 months. Median progression-free survival was 34.2 and 16.9 months for ofatumumab and observation arms, respectively, (hazard ratio, 0.55 [95% confidence interval, 0.43-0.70]; P?

SUBMITTER: van Oers M 

PROVIDER: S-EPMC6893027 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

van Oers Marinus M   Smolej Lukas L   Petrini Mario M   Offner Fritz F   Grosicki Sebastian S   Levin Mark-David MD   Davis Jaclyn J   Banerjee Hiya H   Stefanelli Tommaso T   Hoever Petra P   Geisler Christian C  

Blood cancer journal 20191204 12

We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up to 2 years) or observation. Median follow-up duration was 40.9 months. Median progression-free survival was 34.2 and 16.9 months for ofatumumab and observation arms, respectively,  ...[more]

Similar Datasets

Unknown Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia.
| S-EPMC7430864 | biostudies-literature
Unknown Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
| S-EPMC4571984 | biostudies-other
Unknown Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
| S-EPMC5118034 | biostudies-literature
Unknown Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients.
| S-EPMC5530057 | biostudies-other
Unknown Role of ofatumumab in treatment of chronic lymphocytic leukemia.
| S-EPMC3262343 | biostudies-literature
Unknown Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
| S-EPMC3638632 | biostudies-literature
Unknown Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
| S-EPMC6488229 | biostudies-literature
Unknown Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
| S-EPMC4979101 | biostudies-literature
Unknown Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
| S-EPMC4161365 | biostudies-literature
Unknown Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
| S-EPMC4862586 | biostudies-literature